Document is current
Any future updates will be listed below
-
Authors
Jungholm, Oscar
Trkulja, Carolina
Moche, Martin
Srinivasa, Sreesha P.
Christakopoulou, Maria-Nefeli
Davidson, Max
Reymer, Anna
Jardemark, Kent
Fogaça, Rafaela Lenza
Ashok, Anaswara
Jeffries, Gavin
Ampah-Korsah, Henry
Strandback, Emilia
Andréll, Juni
Nyman, Tomas
Nouairia, Ghada
Orwar, Owe
-
Funding
Funding for this research was provided by:
Karolinska Institutet
Oblique Therapeutics AB
Karolinska Institute
- License Information
-
More Information
Article History
Received: 11 March 2024
Accepted: 13 August 2024
First Online: 23 August 2024
Competing interests
: O.J., M.N.C., K.J., E.S., H.A.K., M.M., J.A., T.N., G.N., and G.J. declare no competing commercial interests. C.L.T., A.R., M.D., R.L.F., A.A., and O.O. declare competing commercial interests. They either are or were employed by Oblique Therapeutics during the preparation of this article. S.P.S. has received consultation fees from Oblique Therapeutics. In addition, C.L.T., M.D., and O.O. hold shares in the company. C.L.T., M.D., and O.O. are inventors on a patent application related to this work filed by Oblique Therapeutics (no. PCT/EP2021/054614, filed 24 February 202 and published 2 September 2021). M.D., C.L.T., S.P.S., and O.O. are inventors on a patent application related to this work filed by Oblique Therapeutics (US provisional 63/175,679 filed 16 April 2021). O.J., M.D., C.L.T., S.P.S., and O.O. are inventors on a patent application related to this work filed by Oblique Therapeutics (US provisional 63/240,052 filed 2 September 2021).
